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Abstract 
The Validation of Genotyping Tests-HPV (VALGENT) studies offer an opportunity to clinically 
validate HPV assays for use in primary screening for cervical cancer and also provide a 
framework for the comparison of analytical and type-specific performance.  Through 
VALGENT, we assessed the performance of the cartridge-based Xpert HPV Assay which 
detects 14 high-risk (HR) types and resolves HPV 16 and HPV 18/45. 
 
Samples from women attending the UK cervical screening programme enriched with 
cytologically abnormal samples were collated. All had been previously tested by a clinically 
validated standard comparator test (SCT) – the GP5+6 EIA. Clinical sensitivity and specificity 
of the Xpert HPV for the detection of CIN2+ and CIN3+ relative to the SCT were assessed as 
was inter and intra lab reproducibility according to international criteria for test validation 
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(1).  Type concordance for HPV 16 and HPV 18/45 between the Xpert and the SCT was also 
analysed. 
 
Xpert HPV detected 94% of CIN2+ and 98% of CIN3+ lesions among all screened women and 
90% of CIN2+ and 96% of CIN3+ in women of 30 years and older. The specificity for ≤CIN1 
was 83% (95% CI 80-85%) in all women and 88% (95% CI 86-91%) in women 30 years and 
older. Inter and intra laboratory agreement for the Xpert was 98% and 97% respectively. The 
kappa agreement for HPV16 and HPV 18/45 between the CVRT (GP5+/6+ LMNX) and the 
Xpert was 0.92 and 0.91 respectively. 
 
The clinical performance and reproducibility of Xpert is comparable to well established HPV 
assays and fulfils the criteria for use in primary cervical cancer screening.  
 
Introduction 
 
Molecular HPV testing is being used increasingly for cervical cancer screening and 
management of (cytology) screen-positive women given the sensitivity and 
objectivity of this approach (2-4). As a consequence, the community is faced with an 
expanding portfolio of HPV tests which vary with respect to target, type-range, 
chemistry and level of automation, many of which are not associated with published, 
peer-reviewed evidence of performance (5). If HPV tests are used for the secondary 
prevention of cervical cancer, it is essential that they are clinically validated and this 
is particularly relevant given that HPV infection often clears without any associated 
morbidity.   
 
International criteria have been established to evaluate the appropriateness of a 
new hrHPV DNA assay based on non-inferior sensitivity and specificity, compared to 
a clinically validated comparator assay, and high reproducibility (1). While they are 
not entirely perfect, they at least represent a consistent standard/benchmark via 
which performance can be assessed. One issue with validating an assay according to 
these criteria is that capturing representative samples which allow verification of 
non-inferior accuracy can be logistically challenging.   
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The VALGENT framework is an international collaboration designed to facilitate the 
clinical validation and comparison of HPV assays that offer genotyping capability (6).  
One of VALGENT’s objectives is to allow the assessment of HPV assays according to 
the aforementioned clinical accuracy criteria, through the use of continuous samples 
from women participating in screening enriched with samples associated with cyto-
pathological abnormalities. 
 
The Xpert HPV Assay (Cepheid, Sunnyvale, CA, USA) is a PCR amplification assay 
which detects 14 HR-HPV types, offers limited genotyping (of HPV 16 and 18/45 as a 
duplex) and can provide a result in around one hour from sample addition. It differs 
from many competitor HPV assays in that the extraction and amplification processes 
are contained within an individual cartridge with minimal operator input other than 
addition of 1 ml of (un-manipulated) original sample (7).  Initial reports on 
performance have been favourable when compared to FDA approved assays in both 
primary screening contexts and colposcopy settings (7-8). However, further data on 
performance pertaining to the Meijer criteria are outstanding, as are data on the 
performance/concordance of the type-specific aspects of the assay. The purpose of 
the present analysis was to address these gaps. 
 
 
Materials and Methods 
Sample Collection 
Samples used for the present analysis constitute the VALGENT-2 panel. A detailed 
description of this panel has been described previously (9-10). In brief, archived 
samples were collated at the cytopathology laboratory at the Royal Infirmary of 
Edinburgh in Scotland which is one of the eight NHS laboratories that serves the 
Scottish Cervical Screening programme and processes around 70,000 samples per 
year. All samples were collected in PreservCyt™ liquid (Hologic, Bedford, MA, USA) 
from August 2012 to October 2012.  The panel contained 1000 consecutive samples 
from the routinely screened population (the Scottish screening set) and 300 
cytologically abnormal samples (the Scottish enrichment set).  With respect to age, 
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as Scotland initiates screening at age 20, 419 samples were from women <30 years 
old, and 881 were from women aged 30 or more.     
 
Ethical approval 
Favourable ethical opinion for the project was provided by the West of Scotland 
Research Ethics Committee 4 - reference:  11/WS/0038 
 
Annotation of samples – HPV status 
All samples had been tested with GP5+/6+ PCR-EIA which was used as the standard 
comparator assay for clinical performance measurement, as per the Meijer criteria 
(1) and which used 0.5 ml of sample input. The amplicon generated via the GP5+/6+ 
PCR-EIA was also subjected to genotyping by the LMNX Genotyping kit HPV GP HR 
(GP5+/6+ LMNX;LBP LaboBiomedicalProducts, Rijswijk, the Netherlands) which uses 
Luminex xMAP technology for genotyping of the follow HPV types: 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66, 68, 26, 53, 73 and 82. The performance of the GP5+/6+ 
EIA and the genotyping provided by the GP5+/6+ LMNX on the VALGENT-2 panel  is 
described in detail  previously by Geraets et al 2014 (10).  Both assays were 
performed at DDL Diagnostic Laboratory, Rijswijk, the Netherlands. The GP5+/6+ EIA 
and GP5+/6+ LMNX assays were performed between theApril -  May 2013 and the  
April - September 2013 respectively.  
The Xpert HPV Assay (Xpert HPV, hereafter) testing was performed at the Scottish 
HPV Reference Laboratory in Edinburgh from the 16th April 2014 to the 14th of 
August 2014 according to manufacturer’s instructions.  Briefly, the assay is CE 
marked and detects 14 high-risk (HR) HPV types: (HPV 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, 68) which are detected simultaneously via amplification of the E6 
and E7 genes in five fluorescent channels: HPV16; HPV18/45; HPV31/33/35/52/58; 
HPV51/59; and HPV39/56/66/68a The assay also incorporates an human control 
gene: : hydroxymethylbilane synthase [HMBS]) as a sample and amplification validity 
check. A total of 1 ml of sample(s) was added to the cartridge before placement on 
to the Cepheid GeneXpert System. 
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Annotation of samples - underlying pathology 
Cytology findings were reported according to the British Society for Clinical 
Cytopathology (BSCC) reporting guidelines with CIN nomenclature used to classify 
histological outcomes (11-13).  Women with abnormal cytology results were 
managed according to guidelines defined by the UK NHS Cervical Screening 
Programme modified for use in the Scotland (13). Colposcopically directed biopsies 
were taken as routinely indicated. Clinical management was not influenced by HPV 
status. 
 
Age specific prevalence of HR-HPV according to Xpert HPV 
Prevalence and 95% confidence intervals of HR-HPV as measured by Xpert HPV was 
assessed in 5 year age-bands within the Scottish screening set.  
 
Assessment of clinical performance and comparison with a clinically validated 
standard comparator test (SCT) 
High grade disease was classed as histologically confirmed CIN2+ within 18 months 
of sample collection within the screening and enrichment set combined (n=101). No 
or low grade disease was assumed when a women either had 2 consecutive, 
cytologically negative samples across two screening rounds (average of 3 years and 
11 months) or had <=CIN1 after having a positive cytology screen (n=842).  
Sensitivity and specificity of Xpert HPV at the level of CIN2+ or CIN3+ was assessed 
for the overall sample set and also for women aged 30 and over separately.  CIN3+ 
incorporated any cancer and also high grade glandular intraepithelial neoplasia.  
Relative sensitivity and specificity of Xpert HPV was compared to the SCT to 
determine whether these measures were lower than 0.90 and 0.98, respectively. 
Non inferiority was assessed by a one-sided statistical test for matched data (14). 
The null hypothesis of inferiority of the Xpert was rejected if P non inf <0.05. The chi2 
test of McNemar was used to assess differences between matched proportions and 
a pMcN  > 0.05 indicated that the sensitivity (or specificity) of Xpert HPV was not 
significantly different from GP5+/6+ EIA.    
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Aggregation of VALGENT-2 data with existing UK Clinical data set  
The sample size for VALGENT2 was computed to assess the performance of assays in 
the Scottish Screening context where screening initiates aged 20 years. To bolster 
data on the performance of Xpert HPV in women aged 30 years and older, VALGENT 
data  were combined with another UK screening based data set described in Cuzick 
et al 2015 (7). As the Meijer 2009 criteria are based on women >30, this aggregation  
(using two UK data sest) ensured the  requisite number of women/outcomes to align 
with said criteria The combined data sets is referred to as the “UK aggregated” data 
set.   In Cuzick et al, 3408 samples obtained from the UK Cervical Screening 
Programme were tested with Xpert HPV, the COBAS HPV Test (Roche Molecular 
Systems, Pleasanton, CA, USA), and the Hybrid Capture 2 HPV Test (hc2) assay 
(Qiagen Ltd, Manchseter, UK) which are both clinically validated HPV screening tests.    
Inter and Intra-lab reproducibility and type-specific agreement  
Inter and intra lab reproducibility was performed according to Meijer criteria which 
specifies that a minimum of 500 samples are assessed of which 30% are positive. 
Intra laboratory testing took place at AML laboratory (Antwerp, Belgium) and inter-
laboratory testing between AML and the laboratory of the University Hospital of, 
Ghent (Ghent, Belgium). A total of 510 samples collated at AML laboratories which 
had previously been tested with an in-house multiplex real-time PCR (15, 16) were 
assessed.  For validation criteria to be satisfied, the 95% lower confidence bound of 
both agreements should be >87%, with a kappa value equal to or exceeding 0.5 (1). 
 
Agreement between Xpert HPV and the GP5+/6+ LMNX for the detection of HPV 16 
and HPV18/ 45 was evaluated using Cohens Kappa statistic. HPV 18/45 were 
reported as a combination by the Xpert HPV “agreement” of the GP5+/6+ LMNX was 
satisfied if it the latter assay was positive for HPV 18 and/or 45 
 
Supplementary data 1 provides an overview of the discrete sample set(s) used for 
the analyses described above. 
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Results  
Demographic, clinical and technical and characteristics of the VALGENT-2 panel 
When considering the Scottish screening and enriched population together – age 
ranged from 15 to 65 years with 881 being over 30 years of age. The average age 
(and range) in the screening and the enrichment set were 38 years (range, 18 to 68 
years)  and 31 years (range 19 to 62 years), respectively.   
In the screening set, 10.2% of samples were cytologically abnormal and 9.2% and 1% 
had low-grade and high grade abnormalities respectively.  In the enrichment set, 
samples were proactively selected for abnormality and incorporated 100 samples 
with borderline nuclear change, 100 with low grade dyskaryosis, and 100 with high 
grade dyskaryosis (moderate) or worse.  Four samples were considered invalid with 
the Xpert HPV by generating a double negative (HPV and housekeeping control) 
result. Of these, 3 of 4 were from the screening set and 1 of 4 from the enrichment 
set.  These samples were excluded from prevalence and accuracy assessments.  Of 
the 1296 evaluable samples, outcomes were available for 943 -  101 were associated 
with histologically confirmed CIN2+ (55 of which were CIN3+) whereas 842 were 
associated with no disease (ie two consecutive negative cytology results or biopsy 
proven <=CIN1). 
 
HR-HPV prevalence as measured by the Xpert  HPV in women attending for routine 
cervical screening in Scotland aged 20-60 
Overall HR-HPV prevalence by Xpert HPV was 18.0% and 11.1 % in women over 30 
years and a total of 34 HPV 16 and 29 HPV 18/45 infections (3.4% and 2.9% 
respectively) were detected in the screening population. Prevalence of hrHPV 
infection by 5-year age group in the screening population is presented in Figure 1.   
 
Clinical performance of Xpert for the detection of CIN2+ 
Agreement between Xpert HPV and the GP5+/6+ EIA, stratified by disease outcomes 
(CIN2+, CIN3+ and  ≤CIN1) for the VALGENT-2 data set is presented in  Table 1 for of 
all ages and for women 30 years or older.  Xpert HPV detected 94% (95% CI 86-98%) 
of CIN2+ and 98% (95% CI 90-100%) of CIN3+ lesions among all screened women and 
93% (95% CI 80-98%) of CIN2+ and 96% (95% CI 79-100%) of CIN3+ in women of 30 
8 
 
years and older. The specificity for identifying women with ≤CIN1 was 83% (95% CI 
80-85%) and 88% (95% CI 86-91%), in all women and in women 30 and older, 
respectively. Table 2 details the absolute and relative accuracy of the Xpert 
compared to the SCT for both the VALGENT data set and the aggregated dataset. In 
addition, cross tabulations of the Xpert vs the SCT are provided in Table 3 for the 
combined data set. The sensitivity and specificity of Xpert HPV was not significantly 
different from GP5+/6+ EIA (Table 2; 95% CI around the relative accuracy measures 
always included unity and pMcN was never significant). Non-inferior sensitivity and 
specificity of Xpert HPV compared to GP5+/6+ EIA was demonstrated for all 
outcomes, except for women of 30 and older, where it was inferior with respect to 
sensitivity for CIN2+ and CIN3+.  However, by combining, VALGENT-2 data with those 
of Cuzick et al 2015 (7), the hypothesis of inferiority was rejected for women aged 
≥30.     
 
Type specific agreement between Xpert HPV and the GP5+/6+ LMNX Assay  
In the screening and enrichment sets combined, 118 HPV 16 infections were 
detected by Xpert HPV compared to 110 by the GP5+/6+ LMNX. A total of 106 
samples were HPV 16 positive for both tests whereas, 12 were HPV 16 positive for 
Xpert HPV only and 4 for GP5+/6+ LMNX only.  The overall concordance for HPV16 
was 98.8% (98.0-99.3%) with a kappa value was 0.923 (95% CI 0.886, 0.960).    
Concordance for presence of HPV18/45 was 99.2% (95% CI 98.5-99.6%) with a kappa 
of 0.915 (95% CI 0.865-0.965). 
 
Inter-laboratory and Intra-laboratory agreement for hrHPV testing with Xpert HPV 
A total of 510 samples were assessed for intra and inter laboratory reproducibility.  
The overall intra-laboratory concordance of hrHPV positivity was 96.9% (95% CI 95.0-
98.2%) with a kappa of 0.925 (95% CI 0.888-0.961) whereas the inter-laboratory 
concordance between initial testing in Antwerp and retesting in Ghent was 97.8% 
(95% CI 96.2-98.9%) with a kappa of 0.948 (95% CI 0.917-0.978).  
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Discussion 
The Xpert HPV is a cartridge based test which detects 14 HR-HPV types and offers 
concurrent limited typing capability. It is a rapid technically undemanding assay and 
integrates extraction and detection within an individual cartridge.  Different levels of 
instrument throughput are available for the assay; from single-module systems to 
80-module systems enabling applications within point of care to settings to high-
throughput centralised service laboratories. 
 
As a relatively new assay there is, understandably, less data on clinical performance 
compared to more established tests.  This said, the data available thus far have been 
encouraging; Einstein et al (2014), assessed the clinical performance of Xpert HPV in 
697 samples obtained from colposcopy referral populations across 7 US sites, with 
performance compared to the COBAS HPV test and the hc2. The Xpert HPV showed 
comparable sensitivity for CIN2+ compared with the COBAS HPV test and hc2 
respectively whereas the highest specificity was conferred by the hc2 followed by 
Xpert HPV and then the COBAS HPV test – leading the authors to conclude that the 
Xpert HPV performance was “comparable to that of currently available clinically 
validated tests” (8). 
 -   
A further analysis of this colposcopy study was performed by Castle et al (2015). 
Here, the authors assessed assay agreement across two samples , and demonstrated 
a high agreement of 95% y. % (17).  This observation of high agreement reconciles 
with the present study where inter and intra-laboratory agreement was also high. 
 
To our knowledge, this is the first study to assess the performance of Xpert HPV 
using the Meijer criteria and accordingly, Xpert HPV fulfils the criteria with respect to 
sensitivity and specificity relative to a clinically validated standard comparator test 
and also inter and intra-laboratory reproducibility. This assessment builds on the 
previous work of Cuzick et al (2015) where a total of 3408 prospective samples 
derived from women attending for routine cervical screening within the UK 
programme and collated across 3 sites were tested with Xpert HPV, hc2 and COBAS 
HPV test. Respective sensitivities of the assays for CIN2 + were 98.7%, 97.5% and 
10 
 
98.7% with specificities of 82.3%, 82.7% and 82.3% (7). Indeed aggregation of this 
data with the VALGENT-2 series allowed more precise assessment of the 
performance of Xpert HPV in women over 30 – an important consideration given 
that many HPV based primary screening protocols stipulate 30 as a minimum age for 
application.   Consistent, with previous work (9) - the data also demonstrate, the 
high prevalence of HR-HPV in the UK, particularly in young women, emphasising the 
need for appropriate triage strategies in an era of HPV primary screening (18). 
 
Like many other HPV assays, Xpert HPV offers limited typing capability –   HPV 16 and 
HPV 18/45.  Type specific agreement for HPV 16 and HPV 18/45 between the Xpert 
and the GP5+/6+ LMNX was high although as the Xpert HPV does not delineate 
between 18/45 separately the concordance between it and the LMNX which does 
provide individual resolution is somewhat artificial.  Further outputs from the 
VALGENT studies will generate more inter-test comparisons for all assays used within 
the projects so that type specific discordances and their relevance can be examined 
more comprehensively.  
 
There are caveats to the analysis – as the timeframe of testing for the GP5+/6+ EIA, 
LMNX and Xpert HPV were not exactly matched it is feasible that this may have 
influenced the results. Furthermore, storage of VALGENT-2 samples prior to testing 
may affect assay performance to an extent. However, if storage were to have a 
deleterious impact on assay-detection a lower sensitivity may be anticipated 
whereas the sensitivity of Xpert HPV for CIN2+ and CIN3+ was high and equivalent or 
higher to that described in the prospective series (7,8). In addition as biopsies were 
only indicated as a consequence of preceding abnormal cytology, some CIN2+ may 
have been missed – although further longitudinal follow up of the cohort – which is 
planned will address this at least in part.    
 
To conclude, the clinical performance and reproducibility of Xpert HPV is comparable 
to standard comparator tests (the hc2, and  the GP5+/6+ EIA) which demonstrated 
better protection against cervical cancer than cytology alone  (1).  Therefore, Xpert 
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HPV may be added to the list of HPV assays considered validated for primary 
screening for cervical cancer (19) 
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Table 1: HR-HPV positivity of Xpert vs GP5+6+ EIA in women attending for routine 
screening in Scotland (ie VALGENT 2 data set) for whom outcome data were 
available. Cross-tabulations are stratified  according to women having CIN2+, CIN3+ 
or two consecutive negative cytology results or ≤CIN1. The left hand section contains 
women of all ages (n=943) whereas the right hand section contains women ≥30 
years of age (n=693).
    Xpert       Xpert 
  
GP5+/6+ 
EIA + - total     
GP5+/6+ 
EIA + - total 
All ages            >=30 years         
CIN2+ 
  
  
  
+ 93 2 95   CIN2+ 
  
  
  
+ 36 1 37 
- 2 4 6   - 2 2 4 
Total 95 6 101   Total 38 3 41 
                  
CIN3+ 
  
  
  
+ 54 0 54   CIN3+ 
  
  
  
 23  0  23  
- 0 1 1   - 0  1  1  
Total 54 1 55   Total 23  1  24  
                  
≤CIN1 
  
  
+ 116 25 141   ≤CIN1 
  
  
+ 55 14 69 
- 30 671 701   - 21 562 583 
Total 146 696 842   Total 76 576 652 
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Age  
group Measure 
Outcome 
(N) 
Absolute accuracy Relative accuracy 
p   McN p  n.inf Xpert SCT Xpert vs SCT , 95% CI 
VALGENT 2 
All ages Sensitivity CIN2+ (101) 94.1% (87.5-97.8%) 94.1% (87.5-97.8%) 1.000 (0.960, 1.042) 1.00 0.0017 
 Sensitivity CIN3+ (55) 98.2% (90.3-100%) 98.2% (90.3-100%) 1.000 (. - .) 1.00 0.0072 
 Specificity ≤CIN1 (842) 
 82.7% (79.9-85.1%) 83.2% (80.6-85.7%) 0.993 (0.972-1.014) 0.50 <0.0001 
≥30 years Sensitivity CIN2+ (41) 90.2% (76.9-97.3%) 92.7% (80.1-98.5%) 0.974 (0.889-1.066) 1.00 0.0951 
 Sensitivity CIN3+ (24) 95.8% (78.9-99.9%) 95.8% (78.9-99.9%) 1.000 (. - .) 1.00 0.055 
 Specificity ≤CIN1 (652) 88.3% (85.6-90.7%) 89.4% (86.8-91.7%) 0.988 (0.968-1.008) 0.24 <0.0001 
AGGREGATED SET 
All ages Sensitivity CIN2+ (180) 96.1% (92.2-984%) 96.1% (92.2-98.4%) 1.000 (0.978-1.023) 1.00 <0.0001 
 Sensitivity CIN3+ (102) 99.0% (94.7-100%) 99.0% (94.7-100%) 1.000 (. - .) 1.00 0.0004 
 Specificity ≤CIN1 (4171) 82.5% (81.3-83.6%) 82.1% (80.9-83.3%) 1.001 (0.992-1.011) 0.76 <0.0001 
≥30 years Sensitivity CIN2+ (68) 92.6% (837-97.6%) 94.1% (85.6-98.4%) 0.984 (0.931-1.040) 1.00 0.019 
 Sensitivity CIN3+ (38) 97.4% (86.2-99.9%) 97.4% (86.2-99.9%) 1.000 (. - .) 1.00 0.021 
 Specificity ≤CIN1 (3206) 88.1% (86.9-89.2%) 87.5% (86.3-88.6%) 1.006 (0.997-1.016) 0.18 <0.0001 
 
Table 2 . Clinical performance of the Xpert compared to a standard, clinically validated comparator tests (hc2 or GP5+6+ EIA)  Absolute sensitivity of the 
tests for CIN2+ or CIN3+ and specificity for ≤ CIN1 are presentedas is relative accuracy of Xpert HPV compared to the comparator tests. The statistical tests 
in the last two columns verify differences (p McNemar) or non-inferiority (P n.inf).  The upper six rows show accuracy measures according to the VALGENT 2 
set where the comparator test was GP5+/6+ EIA,. The aggregated data set incorporates VALGENT 2 and data from Cuzick et al  (7) where the comparator 
test was hc2
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Table 3.  HR-HPV positivity of Xpert vs clinically validated reference test(s) using 
aggregated data from VALGENT 2 and Cuzick et al (2015) 7 Data are stratified 
according to presence or absence of underlying disease and separately for  women 
of all ages and women  ≥30 
 
 
 
 
 
 
 
 
 Xpert 
HC2 or 
GP5+/6+ EIA 
+ - Total 
      CIN2+  Age ≥30 
+ 62 2 64 
- 1 3 4 
Total 63 5 68 
      <CIN2 Age ≥30 
+ 300 100 400 
- 82 2724 2806 
Total 382 2824 3206 
      CIN2+ All Ages 
+ 171 2 173 
- 2 5 7 
Total 173 7 180 
      <CIN2 All ages 
+ 611 130 741 
_ 125 3305 3430 
Total 736 3435 4171 
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Figure 1: HR-HPV prevalence using the Xpert HPV in the routinely 
screened population in Scotland (aged 20-60) 
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Exclude 4 for technical issues (3 from screening 1 from 
enrichment set, n = 1296) 
Supplementary data 1. Overview of samples used for the assessment of prevalence, 
type specific concordance and clinical performance of the Xpert HPV.   
 
Of the VALGENT 2 set (upper image) 1296 samples were technically valid.  HR-HPV 
prevalence (as detailed in figure 1) was assessed using “a” and type specific concordance 
for HPV 16 and 18/45 was assessed using a & b. A total of 943 had follow up/outcome 
data and (c & d) were used for the assessment of clinical performance of the Xpert HPV in 
absolute terms and also in relation to a clinically validated reference test. Clinical 
performance of the Xpert was also assessed by aggregating data from VALGENT 2 with 
that of Cuzick et al 7 (lower image) where a total of 3408 women had follow up/outcome 
data related to the Xpert HPV and a clinically validated reference test, permitting 
assessment of 4351 outcomes (c-f).  Note the samples used for inter and intra-laboratory 
agreement were outside of the above sample pool with this element of the analysis 
performed between Ghent and Antwerp in Belgium.   
Exclude 121 for technical/sample issues, n = 3408 
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